Compare Cytokinetics Inc (CYTK) vs Mongodb Inc (MDB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Mongodb Inc — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.78B), while Mongodb Inc trades at $437.9 (market cap $33.51B). The key difference: Mongodb Inc is far larger — about 3.1× Cytokinetics Inc's market cap, and Mongodb Inc is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals.
| CYTK | MDB | |
|---|---|---|
Market Cap | $10.78B | $33.51B |
Sector | Technology | Technology |
52-Week High | $87.26 | $440.25 |
52-Week Low | $34.31 | $204.37 |
Enterprise Value | $10.88B | $31.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
MongoDB (MDB) trades at $398.8, up 7.78% in the last session, reflecting strong momentum near the consensus price target of $400.39. The stock shows bullish technical signals with support at $384 and resistance at $407. Revenue growth is robust, reaching $2.01B in 2025, though the company remains unprofitable with a net margin of -1.12%. Recent quarters have consistently beaten EPS estimates, and analyst sentiment is overwhelmingly positive with 82% buy ratings.
The outlook for MDB is optimistic due to accelerating revenue growth and AI-driven demand, but risks include persistent losses, high valuation multiples, and competitive pressures. Institutional buying and bullish technical trends support near-term upside, yet profitability challenges warrant caution for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →
